Union Health Minister Mansukh Mandaviya unveiled the world's first intranasal COVID vaccine iNCOVACC. He launched the Bharat Biotech vaccine in the presence of Union Minister of State for Science and Technology, Jitendra Singh on Thursday, January 26. The Union Health ministry said the roll-out of iNCOVACC is expected to begin in private hospitals which have placed advance orders for the same. Although the initial manufacturing capacity of several million doses per annum has been established, it can be scaled up to a billion doses as required. iNCOVACC is priced at Rs 325 per dose for large volume procurement by state governments and the Union government.
The company, in a statement, said the vaccine is now available on CoWIN, and priced at Rs 800 for private markets and Rs 325 for supplies to the Union and state governments. Developed by Bharat Biotech, iNCOVACC is the world's first intranasal COVID-19 vaccine to receive approval for the primary two-dose schedule, and as a heterologous booster dose for adults. It is developed by the Bharat Biotech International Limited (BBIL) in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), a PSU under the Department of Biotechnology, Ministry of Science and Technology.
Mandaviya said that India's vaccine manufacturing and innovation capability is appreciated all over the world as it has made a mark in producing quality and affordable medicines. He also highlighted that BBIL in collaboration with ICMR had introduced Covaxin in India within a month of the launch of the first COVID vaccine in the world. Congratulating BBIL for innovating another vaccine in collaboration with BIRAC, Jitendra Singh said, "India has taken a lead in developing vaccines and medicines for diseases common in the developing world." He added, "The next step will be to develop vaccines for non-communicable diseases."
iNCOVACC is a cost effective COVID vaccine which does not require syringes, needles, alcohol wipes, bandages, and other paraphernalia, thus saving costs related to procurement, distribution, storage and biomedical waste disposal which are routinely required for injectable vaccines, he said. It utilises a vector-based platform, which can be easily updated with emerging variants leading to large scale production, within a few months. These rapid response timelines combined with the ability of cost effective and easy intranasal delivery make it an ideal vaccine to address future infectious diseases, he added.